AstraZeneca Income from Continuous Operations 2010-2024 | AZN

AstraZeneca annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
  • AstraZeneca income from continuous operations for the quarter ending June 30, 2024 was $1.928B, a 5.93% increase year-over-year.
  • AstraZeneca income from continuous operations for the twelve months ending June 30, 2024 was $6.445B, a 4.47% increase year-over-year.
  • AstraZeneca annual income from continuous operations for 2023 was $5.961B, a 81.02% increase from 2022.
  • AstraZeneca annual income from continuous operations for 2022 was $3.293B, a 2763.48% increase from 2021.
  • AstraZeneca annual income from continuous operations for 2021 was $0.115B, a 96.34% decline from 2020.
AstraZeneca Annual Income from Continuous Operations
(Millions of US $)
2023 $5,961
2022 $3,293
2021 $115
2020 $3,144
2019 $1,227
2018 $2,050
2017 $2,868
2016 $3,406
2015 $2,826
2014 $1,235
2013 $2,571
2012 $6,270
2011 $9,950
2010 $8,081
2009 $7,544
AstraZeneca Quarterly Income from Continuous Operations
(Millions of US $)
2024-06-30 $1,928
2024-03-31 $2,180
2023-12-31 $959
2023-09-30 $1,378
2023-06-30 $1,820
2023-03-31 $1,804
2022-12-31 $903
2022-09-30 $1,642
2022-06-30 $360
2022-03-31 $388
2021-12-31 $-346
2021-09-30 $-1,651
2021-06-30 $550
2021-03-31 $1,562
2020-12-31 $1,005
2020-09-30 $651
2020-06-30 $738
2020-03-31 $750
2019-12-31 $277
2019-09-30 $280
2019-06-30 $107
2019-03-31 $563
2018-12-31 $1,009
2018-09-30 $406
2018-06-30 $319
2018-03-31 $316
2017-12-31 $1,261
2017-09-30 $649
2017-06-30 $446
2017-03-31 $512
2016-12-31 $1,817
2016-09-30 $995
2016-06-30 $-31
2016-03-31 $625
2015-12-31 $808
2015-09-30 $770
2015-06-30 $696
2015-03-31 $552
2014-12-31 $-321
2014-09-30 $253
2014-06-30 $797
2014-03-31 $506
2013-12-31 $-520
2013-09-30 $1,248
2013-06-30 $831
2013-03-31 $1,012
2012-12-31 $1,520
2012-09-30 $1,519
2012-06-30 $1,604
2012-03-31 $1,627
2011-12-31 $1,493
2011-09-30 $3,485
2011-06-30 $2,123
2011-03-31 $2,915
2010-12-31 $1,632
2010-09-30 $1,554
2010-06-30 $2,116
2010-03-31 $2,777
2009-12-31 $1,562
2009-09-30 $2,115
2009-06-30 $1,707
2009-03-31 $2,144
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $199.957B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51